Relacorilant, typically used to treat Cushing’s syndrome, could improve outcomes in platinum-resistant cases
A drug originally used to treat a rare disease could extend the lives of patients with an aggressive form of ovarian cancer, according to a clinical trial.
Platinum-resistant ovarian cancer occurs when the disease progresses within six months of starting platinum-based chemotherapy. This form of chemotherapy is different from other types because it uses compounds that contain platinum to destroy cancer cells by preventing them from dividing.
Continue reading…
Source link : https://www.theguardian.com/society/2026/apr/10/drug-extend-survival-aggressive-ovarian-cancer-trial-relacorilant
Author : Tobi Thomas Health and inequalities correspondent
Publish date : 2026-04-10 19:55:00
Copyright for syndicated content belongs to the linked Source.
